Streetbeat News

Analyst Ratings

SMTC

Benchmark analyst Cody Acree has reiterated a Buy rating on Semtech (NASDAQ:SMTC) and maintained a price target of $56.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 10:39 am

SMMT

HC Wainwright & Co. has maintained a Buy rating on Summit Therapeutics and raised the price target from $16 to $30, indicating a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 10:37 am

ELVN

HC Wainwright & Co. has initiated coverage on Enliven Therapeutics with a Buy rating and set a price target of $37.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 10:27 am

ENLV

HC Wainwright & Co. has reiterated its Buy rating for Enlivex Therapeutics, maintaining a price target of $6. Analyst Raghuram Selvaraju continues to support the stock, indicating confidence in its potential.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 10:22 am

CYTK

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating for Cytokinetics (NASDAQ:CYTK) and maintained a price target of $90.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 10:15 am

ORMP

HC Wainwright & Co. has reiterated its Neutral rating on Oramed Pharmaceuticals, indicating no change in their outlook for the company.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 10:13 am

NSA

Keybanc analyst Todd Thomas has downgraded National Storage (NYSE:NSA) from Overweight to Sector Weight, indicating a more cautious outlook on the stock.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 10:08 am

JSPR

JMP Securities has initiated coverage on Jasper Therapeutics with a Market Outperform rating and set a price target of $70.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 10:02 am

DXR

Ascendiant Capital has maintained a Buy rating on Daxor (NASDAQ:DXR) and raised its price target from $24.5 to $24.75, indicating a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 9:57 am

DKNG

Needham analyst Bernie McTernan has reiterated a Buy rating on DraftKings (NASDAQ:DKNG) and maintained a $60 price target.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 9:52 am